Impact of an antimicrobial chewing gum on plaque and gingivitis reduction, salivary pH and oral health-related quality of life in adolescents with fixed orthodontic appliances

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

DRKS

Registry ID

DRKS00030056

Enrollment

Registered

2022-11-07

Start date

2022-12-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K05.0 K05.1

Interventions

Group 1: Test group COVIDGUM: The patient uses chewing gum 4 times a day for 15 minutes each time and otherwise brushes his teeth otherwise brushes his teeth twice a day with fluoride toothpaste as us

Eligibility

Sex/Gender

All

Age

11 Years to 22 Years

Inclusion criteria

Inclusion criteria: - Age between 11 and 22 years - Orthodontic treatment with fixed appliances - Existing gingivitis (according to full-mouth PBI = 60%). - No need for periodontal treatment - No serious general diseases (e.g. syndromal diseases, tumors, Diabetes mellitus, rheumatoid arthritis, etc.) - No use of antibiotics within the last 3 months - No known allergies or intolerances to ingredients of the products to be tested products

Exclusion criteria

Exclusion criteria: None other (see inclusion criteria).

Design outcomes

Primary

Measure	Time frame
Papillary bleeding index (PBI) according to Saxer and Mühlemann and approximal plaque index (API) according to Lange et al. as full-mouth indices.	—

Secondary

Measure	Time frame
Saliva flow rate, pH value and buffer capacity raised with commercially available kit (CRT® buffer, Ivoclar, Schaan, Liechtenstein)	—

Countries

Germany

Contacts

Public ContactFabian Cieplik

Poliklinik für Zahnerhaltung und Parodontologie, Universitätsklinikum Regensburg

fabian.cieplik@ukr.de09419446024

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026